Clinical trial NCT01080664: A Phase I, Dose-escalation Study of AS703569 Given Orally to Subjects With Haematological Malignancies
Official title: A Phase I, Dose-escalation Study of AS703569 Given Orally to Subjects With Haematological Malignancies
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Haematological Malignancies
Keywords: AS703569
Aurora Kinase Inhibitor
Haematological malignancies
Lead sponsor: EMD Serono
Sponsor class: INDUSTRY
First posted: 2010-03-04
Enrollment: 124
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: EMD Serono decided to terminate enrollment based on a review of the available clinical data and low probability of completing the trial based on the observed recruitment rate. Subjects already enrolled in the study continued participation in the study, consistent with the protocol, to study completion.

Detailed description: The goal of this research study is to investigate for the first time the safety and tolerability of a new drug (AS703569), called an aurora kinase inhibitor, being tested to treat blood cancers in patients with different blood cancers. The research study will also assess how the body breaks down AS703569 and what changes occur in the blood after oral doses of AS703569. It will also look to see if there is any improvement in your blood cancer. The use of AS703569 in this study is experimental.

Eligibility criteria: Inclusion Criteria:

Dose-escalation part:

* Primary or secondary acute myeloid leukaemia, including subjects:

with first or subsequent relapse after standard therapy, with no established treatment options; refractory to available therapies, e.g. who failed to achieve complete remission after chemotherapies; Newly-diagnosed elderly subjects (over 60 years) according to WHO classification (≥20 blasts in bone marrow), who did not accept or were not eligible for chemotherapy (first line therapy)

* Subjects with myelodysplastic syndrome (IPSS Int-2 or high risk) resistant or intolerant to standard treatment and not candidates for allogeneic HSCT.
* Subjects with chronic myeloid leukaemia in chronic, accelerated or blast-phase, resistant or intolerant to standard treatment and not candidates for allogeneic HSCT.
* Subjects with myeloproliferative disorders and no effective treatment options.
* Subjects with acute lymphoblastic leukaemia, relapsing, resistant or intolerant to standard treatment and no effective treatment options.
* Subjects with chronic lymphocytic leukaemia, relapsing, resistant or intolerant to standard treatment and no effective treatment options.
* Subjects with non-Hodgkin lymphoma, relapsing, resistant or intolerant to standard treatment with no effective treatment options.

Cohort expansion part

* Primary or secondary acute myeloid leukaemia not eligible for chemotherapy (first line therapy), including subjects

with first or subsequent relapse after standard therapy, for whom no established treatment options are available; refractory to available therapies, e.g. who failed to achieve complete remission after chemotherapies; Newly-diagnosed elderly subjects (over 60 years) according to WHO classification (≥ 20 blasts in bone marrow), who did not accept or were not eligible for chemotherapy (first line therapy)

* Subjects with chronic myeloid leukaemia in chronic or accelerated phase, resistant or intolerant to standard treatment, who have not achieved a complete haematological response, and are not candidates for allogeneic HSCT.
* Subjects with myeloproliferative disorders with no effective treatment options.
* Subjects with Philadelphia chromosome positive acute leukaemias including acute lymphoblastic leukaemia and blast phase chronic myeloid leukaemia, relapsing, resistant or intolerant to standard treatment with no effective treatment options.

Exclusion Criteria:

* Acute promyelocytic leukaemia.
* Ongoing uncontrolled bacterial, viral, fungal or atypical mycobacterial infection.
* Hyperleukocytosis with \>50x10(9)/L leukaemic blasts.
* Chemotherapy, immunotherapy, biologic therapy or any experimental anti-cancer therapy within 28days prior to study Day1 and/or not having recovered from its toxicity.
* Extensive radiotherapy involving ≥30% of bone marrow (e.g. whole pelvis, half spine) within 6months prior to study Day1.
* Active CNS disease involvement.
* Any condition, including laboratory, medical history or pre-study assessment findings, that in the opinion of the Investigator, constitute a risk or contraindication for participation or that could interfere with the study objectives, conduct or evaluation of a drug to be taken orally.
* Clinically relevant cardiac abnormalities or clinically relevant abnormalities .
* Known infection with human immunodeficiency virus, active hepatitis B, or hepatitis C.
* Signs and symptoms suggestive of transmissible spongiform encephalopathy.
* Major surgery within 2weeks prior to study Day1.
* Haemoglobin \<8g/dL at screening (can be transfused).
* Refractory to platelet transfusion (defined as increase of \<20.109/L platelets 1hour after transfusion).
* Coexistent second malignancy or history of prior malignancy within previous 3years (excluding basal or squamous cell carcinoma of the skin, and in situ carcinoma of the cervix that has been treated curatively).

Primary outcomes:
measure: Dose-Limiting Toxicity (DLT)
timeFrame: 21 days or 1 cycle
measure: Preliminary anti-tumour activity
timeFrame: 42 days or 2 cycles
Secondary outcomes:
measure: Treatment-emergent adverse events (TEAE)
timeFrame: minimum 21 days or 1 cycle
Other outcomes:
Locations:
city: San Antonio
country: United States
facility: CTRC at the UT Health Science Center at San Antonio
state: Texas
city: Leuven
country: Belgium
facility: Haematologie UZ Gasthuisberg
city: Yvoir
country: Belgium
facility: Mont-Godinne University Hospital (UCL)
city: Frankfurt am Main
country: Germany
facility: Universitatsklinik Frankfurt
city: Munchen
country: Germany
facility: Technische Universitat Munchen
city: Ulm
country: Germany
facility: Medizinische Universitatsklinik
city: Bologna
country: Italy
facility: Policlinico Sant'Orsola Malpighi
city: Basel
country: Switzerland
facility: Kantonsspital Basel
city: Geneva
country: Switzerland
facility: Hospitaux Universitaires
city: St Gallen
country: Switzerland
facility: Kantonsspital St Gallen
Study officials:
affiliation: Merck Serono S.A., Geneva
name: Narmyn Rejeb, M.D.
role: STUDY_DIRECTOR
References:
citation: Graux C, Sonet A, Maertens J, Duyster J, Greiner J, Chalandon Y, Martinelli G, Hess D, Heim D, Giles FJ, Kelly KR, Gianella-Borradori A, Longerey B, Asatiani E, Rejeb N, Ottmann OG. A phase I dose-escalation study of MSC1992371A, an oral inhibitor of aurora and other kinases, in advanced hematologic malignancies. Leuk Res. 2013 Sep;37(9):1100-6. doi: 10.1016/j.leukres.2013.04.025. Epub 2013 Jun 5.